Detalhe da pesquisa
1.
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Lancet
; 402(10397): 185-195, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37290461
2.
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 400(10358): 1103-1116, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36099926
3.
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
JAMA Oncol
; 8(2): 275-280, 2022 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34940781